These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Angiogenesis and antiangiogenic cancer therapy]. Pour L; Hájek R; Buchler T; Maisnar V; Smolej L Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808 [TBL] [Abstract][Full Text] [Related]
6. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use]. Plavetić ND; Letilović T; Vrbanec D Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217 [TBL] [Abstract][Full Text] [Related]
8. Tumor angiogenesis--a potential target in cancer chemoprevention. Bhat TA; Singh RP Food Chem Toxicol; 2008 Apr; 46(4):1334-45. PubMed ID: 17919802 [TBL] [Abstract][Full Text] [Related]
9. Vascular targeting and the inhibition of angiogenesis. Bicknell R Ann Oncol; 1994; 5 Suppl 4():45-50. PubMed ID: 7520262 [TBL] [Abstract][Full Text] [Related]
10. Tumor angiogenesis: biology and therapeutic prospects. Harris SR; Thorgeirsson UP In Vivo; 1998; 12(6):563-70. PubMed ID: 9891218 [TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic cancer therapy. Cao Y Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898 [TBL] [Abstract][Full Text] [Related]
12. [The clinical perspective of angiogenesis inhibitors]. Radema SA; Witteveen PO; Gebbink MB; Voest EE Ned Tijdschr Geneeskd; 2003 Aug; 147(35):1675-80. PubMed ID: 14513538 [TBL] [Abstract][Full Text] [Related]
13. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Pradeep CR; Sunila ES; Kuttan G Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508 [TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic strategies for cancer therapy (Review). Benouchan M; Colombo BM Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440 [TBL] [Abstract][Full Text] [Related]
15. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Lingen MW; Polverini PJ; Bouck NP Cancer Res; 1998 Dec; 58(23):5551-8. PubMed ID: 9850093 [TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
17. Current strategies and future directions of antiangiogenic tumor therapy. Zhang ZL; Wang JH; Liu XY Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Cao Y Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094 [TBL] [Abstract][Full Text] [Related]